{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:24:04Z","timestamp":1784334244759,"version":"3.55.0"},"reference-count":33,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":663,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2000,3]]},"abstract":"<jats:sec><jats:title>Objective:<\/jats:title><jats:p>Furazolidone, an old but cheap antibiotic, was shown to be a good alternative to metronidazole in triple therapy for <jats:italic>Helicobacter pylori<\/jats:italic> eradication in areas where metronidazole resistant bacteria are common, but randomized studies are lacking.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim:<\/jats:title><jats:p>A randomized controlled trial to determine the efficacy and safety of furazolidone compared to metronidazole in classic quadruple therapy for eradication of <jats:italic>H. pylori<\/jats:italic> infection in duodenal ulcer patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Patients with endoscopically proven duodenal ulcer and positive urease test were randomized to receive ranitidine 300\u2003mg, amoxycillin 1000\u2003mg and bismuth subcitrate 240\u2003mg b.d, with either furazolidone 200\u2003mg b.d (RABF), or metronidazole 500\u2003mg b.d. (RABM) for 2\u2003weeks. Compliance and side\u2010effects were monitored and recorded by table diary. <jats:italic>H. pylori<\/jats:italic> eradication was assessed at least 4\u2003weeks after the completion of therapy with <jats:sup>14<\/jats:sup>C\u2010urea breath test.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>A total of 106 patients were enrolled and 101 (59\u2003male, 42 female, mean age=40\u2003\u00b1\u200311\u2003years) completed the study. Endoscopic findings and demographic data were comparable in both groups. Intention\u2010to\u2010treat eradication rates were 75% and 55% (<jats:italic>P<\/jats:italic>=0.03) and per protocol eradication rates were 82 and 56% (<jats:italic>P<\/jats:italic>=0.006) in the RABF and RABM groups, respectively. Side\u2010effects were reported by 13 patients (27%) in the RABF group (one stopped treatment) compared to five patients (10%) in the RABM group (<jats:italic>P<\/jats:italic>=0.04).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Quadruple therapy containing furazolidone, instead of metronidazole, results in a significantly higher <jats:italic>H. pylori<\/jats:italic> eradication rate in Iranian duodenal ulcer patients.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2000.00709.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:41:09Z","timestamp":1047354069000},"page":"299-303","source":"Crossref","is-referenced-by-count":35,"title":["Furazolidone versus metronidazole in quadruple therapy for eradication of <i>Helicobacter pylori<\/i> in duodenal ulcer disease"],"prefix":"10.1111","volume":"14","author":[{"family":"Malekzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Vahedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Siavoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Eshraghian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Vakili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Saghari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Massarrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.1994.03520010077036","article-title":"Helicobacter pylori in peptic disease. NIH Consensus conference","volume":"272","author":"NIH consensus development panel on Helicobacter pylori ulcer disease","year":"1994","journal-title":"J Am Med Assoc"},{"key":"e_1_2_6_3_2","first-page":"116","article-title":"Helicobacter pylori","volume":"89","author":"Marshall BJ","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_4_2","first-page":"2025","article-title":"Helicobacter pylori recurrence after successful eradication: 5\u2010year follow\u2010up in the United States","volume":"92","author":"Abu\u2010Mahfouz MZ","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1994.tb00303.x"},{"key":"e_1_2_6_6_2","first-page":"1419","article-title":"Effect of triple therapy or amoxicillin plus omeprazole or amoxicillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori and prevention of ulcer replace over a 1\u2010year follow\u2010up period: a prospective, randomized, controlled study","volume":"90","author":"Saber\u2010Firoozi M","year":"1995","journal-title":"Am J Gastroentrol"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)80692-6"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)80861-5"},{"key":"e_1_2_6_9_2","first-page":"A2218","article-title":"Effect of two different doses of metronidazole and tetracycline in classic triple therapy on eradication of H. pylori and its metronidazole resistant strains","volume":"112","author":"Salman\u2010Raoghani H","year":"1997","journal-title":"Gastroenterology"},{"key":"e_1_2_6_10_2","first-page":"A126","article-title":"Effect of furazolidone bismuth subcitrate and amoxicillin for eradication of Helicobacter pylori in Iran","volume":"112","author":"Malekzadeh R","year":"1997","journal-title":"Gastroenterology"},{"key":"e_1_2_6_11_2","first-page":"592","article-title":"Furazolidone, amoxicilline, bismuth triple therapy for Helicobacter pylori infection","volume":"11","author":"Segure AM","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)91501-2"},{"key":"e_1_2_6_13_2","first-page":"1027","article-title":"Mini\u2010dose (1\u2010micro\u2010ci) 14C urea breath test for detection of Helicobacter pylori","volume":"89","author":"Raju GS","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.1996.tb00003.x"},{"key":"e_1_2_6_15_2","unstructured":"TytgatGNY. Aspects of Anti\u2010Helicobacter pylori Basic Mechanism to Clinical Cure. Dordrecht: Kluwer Academic Publisher 1996: 304\u201347."},{"key":"e_1_2_6_16_2","first-page":"A105","article-title":"Mertonidazole and clarithromycin resistance among H. pylori isolates from a large hospital in the United States","volume":"112","author":"Osato MS","year":"1997","journal-title":"Gastroenterology"},{"key":"e_1_2_6_17_2","first-page":"A236","article-title":"Metronidazole resistance is high in Korea and Colombia and appears to be rapidly increasing in the U.S","volume":"110","author":"Reddy R","year":"1996","journal-title":"Gastroenterology"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1994.tb00170.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/jama.1996.03530320046033","article-title":"Consenses conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice parameters committee of American College of Gastroenterology","volume":"275","author":"Soll AH","year":"1996","journal-title":"J Am Med Assoc"},{"key":"e_1_2_6_20_2","first-page":"1203","article-title":"Clarithromycin, Tetracycline, and bismuth: a new non\u2010metronidazole therapy for Helicobacter pylori infection","volume":"89","author":"Al\u2010Assi AT","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_21_2","unstructured":"KatzungBG. Basic Clinical Pharmacology. 2nd edn. California: Lange 1984."},{"key":"e_1_2_6_22_2","unstructured":"GothA. Medical Pharmacology. 10th edn. St. Louis: CV Mosby 1981."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365528909091325"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1992.tb01034.x"},{"key":"e_1_2_6_25_2","unstructured":"Goodman GilmanA RollTW NicsAS TaylorP.Pharmacological Basis of Therapeutics. 8th edn. NewYork: Pergmon Press 1991."},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)91653-8"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)90324-1"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)92639-5"},{"key":"e_1_2_6_29_2","first-page":"233","article-title":"In vivo susceptibility of Campylobacter pylori","volume":"84","author":"Graham DY","year":"1989","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.9.1637"},{"key":"e_1_2_6_31_2","first-page":"A244","article-title":"In vitro sensitivity of Hp to antibiotics","volume":"116","author":"Pourkhajeh A","year":"1999","journal-title":"Gastroenterology"},{"key":"e_1_2_6_32_2","first-page":"503","article-title":"The efficacy of furazolidone and metronidazole in the treatment of chronic gastritis associated with. Compilobacter pylori","volume":"37","author":"Xiao SD","year":"1990","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(88)90348-4"},{"key":"e_1_2_6_34_2","first-page":"971","article-title":"Five days bismuth free triple therapy for the eradication of Helicobacter pylori and reduction of duodenal ulcer relapse","volume":"86","author":"Coelho LG","year":"1991","journal-title":"Am J Gastroenterol"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2000.00709.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2000.00709.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2000.00709.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T16:38:57Z","timestamp":1698597537000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2000.00709.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,3]]}},"alternative-id":["10.1046\/j.1365-2036.2000.00709.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2000.00709.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,3]]}}}